Advances in genomics and proteomics has enabled researchers to uncover the molecular events that are the underlying basis for developing a disease. Often a combination of genetic changes either through spontaneous mutations or inheritance, lead to this disease state. Identifying and understanding these molecular changes has driven clinicians and researchers to diagnose and treat disease in a novel way.

Pathology, the discipline of physical identification of disease within tissue or cells, has now become the center point to ascertain exactly what is problem and if or how it may be treated. Visualization of excised tissue or isolated circulating tumor cells involves multiplex immunohistochemistry or mIHC. mIHC, involves using highly specific stains to identify molecular markers that are disease specific. Gone are the days of labeling cancer based on the organ or site of identification. Today, the underlying genetic changes that leads to the disease is identified and appropriate treatments are recommended.

As in mass spectrometry, the equipment for mIHC was designed for research labs. This equipment is exceedingly expensive and has not been designed for hundreds or thousands of clinical samples. Based on our partnership with a leading mIHC service laboratory in China, we will develop a vastly lower cost IHC multiplex cell analysis platforms specifically designed for the clinical market. We also see exceptional opportunity to bring solutions for single cell analysis, digital/next generation pathology for treatment involving checkpoint inhibitors and immune modulators.